Hans Peter Hasler

About Hans Peter Hasler

Independent director of Gain Therapeutics since January 2021; age 69 per the 2025 proxy. Career spans senior operating roles at Biogen (COO; EVP; Head of Global Neurology & International), Elan (COO), and Wyeth (SVP/CMO; country leadership roles). Education: Federal Swiss Commercial Diploma and Marketing Manager Certificate from the Swiss Institute of Business Economy (SIB), Zurich. Board biography cites 30+ years in biotech/pharma and current leadership across several public companies .

Past Roles

External Roles

Board Governance

• Committee assignments: Audit Committee member; Nominating & Corporate Governance (NCG) Committee Chair .
• Independence: Affirmatively determined independent under Nasdaq rules .
• Attendance: Board met four times in FY2024; each director attended 100% of Board and relevant committee meetings. FY2024 committee meetings—Audit: 4; Compensation: 4; NCG: 4 .
• Board leadership structure: Chairman of the Board is Khalid Islam (separate from CEO), with responsibilities including executive sessions of independent directors .

Fixed Compensation

Context: Non-employee director cash retainers—$40,000 annual; $11,000 NCG chair; $7,500 Audit member; other committee fees as specified in policy .

Performance Compensation

Equity structure and vesting:

• Annual non-employee director option awards: 15,000 shares vesting monthly over 12 months; initial appointment awards: 42,000 shares vesting over 3 years; options have 10-year terms; change-in-control accelerates vesting .
• June 23, 2023 supplemental director awards: 10,500-share options (one-year cliff) due to timing of policy adoption .

Other Directorships & Interlocks

• Related-party transactions: Proxy discloses related-party exposure with Minoryx via Chairman Khalid Islam (royalty license); no transactions disclosed involving Hasler .

Expertise & Qualifications

• Operating and international leadership across Big Pharma (Biogen, Elan, Wyeth) and commercialization/marketing roles .
• Board and capital markets experience leading HBM Healthcare Investments and UK-listed Shield Therapeutics .
• Education in Swiss commercial and marketing disciplines (SIB, Zurich) .
• NCG committee leadership and governance oversight at GANX .

Equity Ownership

• Shares pledged/hedging: Company insider trading policy prohibits hedging, short selling, margin accounts, and pledging of company securities .

Governance Assessment

• Committee leadership and independence: As NCG Chair and Audit member, Hasler is positioned to drive governance standards; independence affirmed under Nasdaq . Positive signal for board effectiveness.
• Attendance: 100% Board and committee attendance in FY2024 supports engagement and diligence .
• Shareholder support signal: 2025 director election votes for Hasler—For: 9,149,943; Withheld: 977,417; Broker non-votes: 8,426,391. The withheld votes indicate some investor scrutiny relative to peers with higher “For” tallies; continued engagement advisable .
• Compensation alignment: Cash fees reflect committee responsibilities; equity is time-vested options with change-in-control protection; no performance conditions for director equity, typical for small-cap biotech governance structures .
• Conflicts/related-party transactions: None disclosed for Hasler; broader related-party exposure exists with Minoryx via Chairman Islam, monitored by Audit Committee per policy .
• Risk indicators:
  • Overboarding watchpoint: Concurrent leadership roles at HBM (Chairman), Shield (Nonexec Chairman), Minerva (Director) plus advisory responsibilities may raise time-commitment concerns for some investors; currently no independence impairment disclosed .
  • Hedging/pledging prohibited—alignment preserved by policy .
  • Say-on-pay history not applicable to directors in disclosures; no low approval votes noted.

Additional Signals and Data